292 related articles for article (PubMed ID: 1395069)
1. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
van der Lely AJ; Harris AG; Lamberts SW
Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue.
Yang IM; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK
Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
4. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
[TBL] [Abstract][Full Text] [Related]
5. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
[TBL] [Abstract][Full Text] [Related]
6. Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group.
Arosio M; Macchelli S; Rossi CM; Casati G; Biella O; Faglia G
Eur J Endocrinol; 1995 Oct; 133(4):430-9. PubMed ID: 7581966
[TBL] [Abstract][Full Text] [Related]
7. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
Riedel M; Günther T; von zur Mühlen A; Brabant G
Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
[TBL] [Abstract][Full Text] [Related]
8. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
[TBL] [Abstract][Full Text] [Related]
9. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
[TBL] [Abstract][Full Text] [Related]
10. Bioactive GH-like immunoglobulins G in active acromegaly: response to long-term treatment with bromocriptine.
Campino C; Szecowka J; Lopez JM; Seron-Ferre M
Clin Endocrinol (Oxf); 1995 Jul; 43(1):111-6. PubMed ID: 7641402
[TBL] [Abstract][Full Text] [Related]
11. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
Fredstorp L; Kutz K; Werner S
Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
[TBL] [Abstract][Full Text] [Related]
12. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
13. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
14. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly].
Gasińska T; Nowak S
Endokrynol Pol; 1993; 44(4):455-65. PubMed ID: 8055814
[TBL] [Abstract][Full Text] [Related]
15. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly.
Haraguchi K; Ohtaka M; Takazawa K; Endo T; Onaya T
Endocr J; 1995 Apr; 42(2):295-300. PubMed ID: 7627275
[TBL] [Abstract][Full Text] [Related]
16. A close correlation between the inhibitory effects of insulin-like growth factor-I and SMS 201-995 on growth hormone release by acromegalic pituitary tumours in vitro and in vivo.
Lamberts SW; van Koetsveld P; Hofland L
Clin Endocrinol (Oxf); 1989 Oct; 31(4):401-10. PubMed ID: 2627746
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of GH paradoxical responses to TRH and LHRH in acromegalic patients during long-term treatment with octreotide.
Merola B; Colao A; Cataldi M; Rossi E; Selleri A; Briganti F; Schettini G; Bellastella A; Lombardi G
Horm Res; 1992; 37(1-2):18-22. PubMed ID: 1398471
[TBL] [Abstract][Full Text] [Related]
18. Differential response to aminergic stimuli and biological behavior of growth hormone secreting pituitary adenomas.
Fanghanel G; Larraza O; Villalobos M; Fanghanel L; Velasco M; Velasco F
Can J Neurol Sci; 1990 Feb; 17(1):78-82. PubMed ID: 2107017
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
20. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
